The Daily Pulse

Health

Drugmaker Gilead arranges generic production deals for experimental Ebola prevention treatment

Reported by Ishita Mukherjee (Staff Writer) · The Hindu - Health ·

Source: The Hindu
Worth knowing
Drugmaker Gilead arranges generic production deals for experimental Ebola prevention treatmentPhoto: Wikimedia Commons

Gilead Sciences has struck non-fee agreements with three drug manufacturing firms to supply its experimental Ebola prevention medicine across 127 low- and lower-middle-income nations upon successful clinical trials and official approvals. Dr. Reddy's Laboratories, Eva Pharma, and Ferozsons Laboratories are the three companies partnering in these pacts, which specifically include every African nation currently dealing with the active Ebola Bundibugyo outbreak.

Trial Status

The medicine involved is obeldesivir, which has displayed activity against multiple viruses related to Ebola during laboratory research though it lacks approval anywhere globally. A late-stage clinical trial is presently evaluating the compound on individuals facing high exposure risks. These commercial partnerships aim to set up production networks and supply chains in advance of trial conclusions and official regulatory submissions. Gilead is additionally broadening existing remdesivir licensing agreements to encompass Ebola-related illnesses pending positive trial outcomes and regulatory clearances.

Donations

The corporation has already supplied over 38,000 vials of remdesivir to Uganda, the Democratic Republic of Congo, and Kenya. This total includes upwards of 2,000 vials recently dispatched to Kenya for investigative care and post-exposure prevention efforts. Regulators have not approved remdesivir to manage or prevent Ebola Bundibugyo disease, and health authorities have not proven its clinical effectiveness.

Context

Experimental treatments typically undergo extensive clinical testing phases before health authorities consider them for public distribution or emergency use during outbreaks. Early manufacturing agreements help companies prepare large-scale medical supplies so treatments can reach affected populations quickly if clinical evaluations succeed.

Read more at The Hindu - Health →